The FDA approved Fylnetra, the fifth approval for a pegfilgrastim biosimilar in the United States.
The FDA has approved the fifth pegfilgrastim biosimilar for the US market, Amneal Pharmaceuticals and Kashiv Biosciences’ Fylnetra (pegfilgrastim-pbbk), referencing Neulasta.
Fylnetra is the third biosimilar developed by Amneal Pharmaceuticals and the second for Kashiv Biosciences to be authorized for US marketing. The approval follows those for Releuko (filgrastim-ayow) and Alymsys (bevacizumab-maly). All 3 approvals have been for oncology biosimilars.
“This is our third US biosimilar approval this year, and we are very enthusiastic about our future in the fast growing $28 billion US biosimilars market,” said Chirag and Chintu Patel, co-chief executive officers of Amneal Pharmaceuticals, in a company statement. "Biosimilars represent the next wave of affordable medicines and are closely aligned with our mission to provide high quality, affordable medicines to as many patients as possible."
Pegfilgrastim products are used to treat or prevent febrile neutropenia in patients with cancer being treated with chemotherapy. Amneal Pharmaceutcials said that it expects to launch Releuko, Alymsys, and Fylnetra during the second half of 2022.
“Building on our successful partnership with the recent approval of our first biosimilar, Releuko, we are pleased to receive approval for our second biosimilar,” said Chandramauli Rawal, MBBS, chief operating officer for Kashiv Biosciences. "Kashiv is one of a few domestic companies to manufacture and launch multiple biosimilars in the United States. Kashiv aims to continue bringing high quality biosimilars to the global markets over the coming years. I would like to extend a humble thank you to our highly talented team, without whom this would not have been possible."
Fylnetra will join Nyvepria (pegfilgrastim-apgf), Ziextenzo (pegfilgrastim-bmez), Udenyca (pegfilgrastim-cbqv), and Fulphila (pegfilgrastim-jmdb) in competing against the originator in the United States. Fulphila was the first pegfilgrastim biosimilar to be approved in June 2018, followed by Udenyca in November 2018, Ziextenzo in November 2019, and Nyvepria in June 2020.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.